Antitumor effect of 131 I-labeled anti-VEGFR2 targeted nanoparticles in anaplastic thyroid carcinoma mouse models
10.3760/cma.j.issn.2095-2848.2018.11.002
- VernacularTitle:131I标记抗VEGFR2靶向性纳米载体对未分化甲状腺癌的抑瘤作用
- Author:
Renfei WANG
1
;
Ruiguo ZHANG
;
Yueqian ZHANG
;
Hongbin CHEN
;
Ning LI
;
Fuhai ZHANG
;
Hanjie WANG
;
Jin CHANG
;
Guizhi ZHANG
;
Jian TAN
Author Information
1. 300052,天津医科大学总医院核医学科
- Keywords:
Thyroid neoplasms;
Vascular endothelial growth factor receptor-2;
Nanoparticles;
Iodine radioisotopes;
Tomography;
emission-computed;
single-photon;
Tomography;
X-ray computed;
Mice;
nude
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2018;38(11):716-720
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the radioactivity distribution of 131 I-bovine serum albumin ( BSA )-mesoporous silica nanoparticles ( MSNs )-anti-vascular endothelial growth factor receptor 2 (VEGFR2) in anaplastic thyroid carcinoma (ATC) and to explore its antitumor efficacy in ATC-bearing nude mouse models. Methods 131 I-BSA-MSNs-anti-VEGFR2 and 131 I-BSA-MSNs were constructed. FRO tumor xenografts were established and the SPECT/CT images of tumor-bearing mice were acquired at differ-ent time points after intratumoral injection with 131 I-BSA-MSNs-anti-VEGFR2 ( targeting group) , 131 I-BSA-MSNs ( non-targeting group) , Na131 I ( Na131 I group) and saline ( control group) , respectively. The changes of body mass and tumor volume in each group were recorded. Two-sample t test and log-rank test were used to analyze the data. Results After incubation for 3 h, the fluorescence intensity in targeting group was higher than that in non-targeting group (345.26±16.35 vs 280.61±9.65;t=5.90, P<0.05). After injection for 1-3 weeks, the radioactivity detected by SPECT/CT in targeting group was obviously stronger than that in non-targeting group ( t values:7.060-12.780, all P<0.05) . At the end of the observation, the tumor vol-ume of Na131I group, control group, non-targeting group and targeting group increased to (278.3±19.3)％, (296.6±24.2)％, (198.7±13.2)％ and (103.7±6.2)％ of the original volume, respectively. The body mass of the first 2 groups decreased to (88.6±3.0)％ and (86.2±3.1)％ of the original body mass respec-tively, while that of the latter 2 groups increased to (102.1±3.1)％ and (116.2±3.4)％ of the original body mass respectively. Survival analysis showed that the median survival time in targeting group ( 38 d) was sig-nificantly longer than that in non-targeting group (34 d;χ2=8.05, P<0.05). Conclusion 131I-BSA-MSNs-anti-VEGFR2 can effectively inhibit the tumor growth of ATC and prolong the survival of tumor-bearing nude mice, which gives a good suggestion for the treatment and prognosis evaluation of ATC.
